The pursuit of quality of life and attention to physical health are not contradictory, but in the context of the continuous aggravation of overweight and obesity problems, how to identify the related risks of weight management and establish scientific management awareness while enjoying life is becoming an increasingly important public health issue. Truly sustainable weight management requires a balance between safety, tolerability, and daily feasibility, in addition to the weight loss effect, to make scientific plans more comfortably integrated into life.
In recent years, weight loss treatment plans represented by GLP-1 receptor agonists have been continuously iterated, providing more options for clinical practice. Professor Wu Jing introduced that the new generation of biased GLP-1 receptor agonists provide more evidence-based support for balancing efficacy, safety, and long-term management through a G-protein biased signal activation mode. Simply put, these drugs tend to activate signaling pathways related to weight loss and reduce signals associated with adverse reactions, thereby achieving a better balance between efficacy and tolerability.
